Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients

European Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2013, Pages 1285-1291

  Singkham, Noppaket ^a   Towanabut, Somchai ^b   Lertkachatarn, Surang ^b   Punyawudho, Baralee ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PRASAT NEUROLOGICAL INSTITUTE   (Thailand)

Author keywords

Lamotrigine; Population Pharmacokinetics; UGT polymorphisms

Indexed keywords

ADENINE; CARBAMAZEPINE; CYTOSINE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B7; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; THYMINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; EPILEPSY; ETHNIC GROUP; FEMALE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THAI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND; TRIAZINES; YOUNG ADULT;

EID: 84878011144     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1449-5     Document Type: Article

References (29)

1. Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061-1075
2. Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47:752-760
3. Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48:455-463
4. Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dominguez-Gil A, Garcia MJ (2008) Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483-489
5. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39:373-384
6. Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457-465
7. Miners JO, McKinnon RA, Mackenzie PI (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182:453-456
8. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP- glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33:672-675
9. Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77
10. Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4
11. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83:595-600
12. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062
13. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685
14. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739
15. Innocenti F, Liu W, Fackenthal D, Ramirez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18:683-697
16. Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048-1054
17. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1-8
18. Blanca Sanchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Shushtarian M, Armijo JA (2010) UGT2B7-161C > T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32:177-184
19. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, Lai AA, Hubbell J, Chern WH, Allsup T, et al. (1991) Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 10:191-200
20. Beal SL, Sheiner LB, Boeckmann AJE (1989-2006) NONMEM users guides. University of California, San Francisco
21. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64
22. Jadhav PR, Gobburu JV (2005) A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 7:E523-E531
23. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
24. Chan V, Morris RG, Ilett KF, Tett SE (2001) Population pharmacokinetics of lamotrigine. Ther Drug Monit 23:630-635
25. Patsalos PN, Froscher W, Pisani F, van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365-385
26. Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, Sabers A (2007) Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48:484-489
27. Lalic M, Cvejic J, Popovic J, Bozic K, Golocorbin-Kon S, Al-Salami H, Mikov M (2009) Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 34:93-99
28. Yafune A, Ishiguro M (1999) Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. Stat Med 18:581-599
29. Booth BP, Gobburu JV (2003) Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol 43:1307-1315